Senate Democrats Unveil Health Care Affordability Framework
Twelve Senate Democrats and the Center for American Progress release a health care cost control framework aimed at shaping future legislative priorities.
Clinical Research
The latest clinical research coverage from Hawaii Medical Journal.
FDA Backs Domestic Drug Production to Counter China
The FDA has proposed policies to boost domestic drug manufacturing, including giving U.S. generic makers a patent challenge head start over foreign rivals.
FDA Delay Forces Kezar Life Sciences to Close Its Doors
A four-month FDA meeting cancellation proved fatal for Kezar Life Sciences, highlighting how regulatory delays can devastate small biotech companies.
FDA Delays Force Kezar Life Sciences to Shut Down
Kezar Life Sciences is winding down after FDA meeting cancellations disrupted its autoimmune hepatitis drug program, driving investors to withdraw funding.
FDA Approves Lilly's Orforglipron; Trump Pharma Tariffs Loom
FDA approves Eli Lilly's oral obesity pill orforglipron (Foundayo) while Trump eyes 100% tariffs on imported pharmaceuticals and drug ingredients.
FDA Eyes Reversal on Peptide Compounding Ban
The FDA signals a reversal of its 2023 peptide compounding ban, raising patient safety concerns, while gene therapy researchers face manufacturing hurdles.
By James Liu
Sarepta Therapeutics Shares Surge on Rare Disease Drug Data
Sarepta Therapeutics shares rose 20% after releasing early clinical data for two rare muscle-wasting disease candidates, SRP-1001 and SRP-1003.
Electronic Marking Systems to Prevent Medical Exam Errors
The AoMRC has issued guidance urging royal colleges to adopt electronic marking systems after a blunder affected nearly 300 physician exam candidates.
FDA Approves Kresladi Gene Therapy for Rare LAD-1 Disease
The FDA has approved Rocket Pharma's Kresladi for LAD-1, a rare immunodeficiency affecting roughly 25 US patients annually, marking a gene therapy milestone.
By Robert Kim
How to Become a More Compassionate Clinical Leader
Discover evidence-based principles of compassionate leadership in healthcare, addressing physician burnout and workforce retention in clinical settings.
By Robert Kim
Novo Nordisk Faces Investor Pressure at 2026 Annual Meeting
Novo Nordisk faces shareholder scrutiny as its stock drops 45% since CEO ouster, while rival Eli Lilly surges to a $1 trillion market cap.
Fall Prevention in Stroke Survivors: Tailored Interventions Work
Stroke survivors face 1.5x higher fall risk. New Australian trial evidence supports home-based, individualized programs to reduce falls in this vulnerable group.
By Sarah Tanaka
Trump Drug Pricing Flaw & Gilead Deal: What to Know
A structural gap in Trump's most-favored nation drug pricing framework raises doubts, while Gilead Sciences makes a major autoimmune therapeutics acquisition.
By Robert Kim
FAST Trial: Home Intervention Cuts Falls After Stroke by 33%
A randomised trial shows a tailored home-based physiotherapy intervention reduces fall rates by one third in community-dwelling stroke survivors.
By Priya Patel
Rethinking eGFR Monitoring in Chronic Kidney Disease
New evidence challenges single eGFR measurements in CKD, suggesting GFR decline trajectory is more clinically actionable than point-in-time precision.
By Sarah Tanaka
Apogee's Zumilokibart Shows Promise for Eczema in 2026
Apogee Therapeutics' zumilokibart showed skin clearance and itch relief for atopic dermatitis with less frequent injections in mid-stage trial results.
By Robert Kim
Iran Conflict, Pharma Supply Chain & Pfizer Lyme Vaccine
Analysts warn Iran conflict could disrupt pharma supply chains via Strait of Hormuz, while Pfizer's Lyme disease vaccine shows promise in Phase 3 trials.
By Sarah Tanaka
VATS vs Open Lobectomy Survival: IPD Meta-Analysis
A Lancet IPD meta-analysis finds VATS lobectomy significantly improves overall survival versus open thoracotomy in early-stage NSCLC patients.
Hydration for Kidney Stones: RCT Adherence Intervention
A Lancet RCT tested a structured hydration intervention for urinary stone prevention, finding modest urine output gains but no significant reduction in recurrence.
By James Liu
Surgical Approach and Long-Term Lung Cancer Outcomes 2026
A Lancet commentary argues surgical technique is a key variable in lung cancer outcomes, urging rigorous trial design to evaluate minimally invasive approaches.
CMS Chief Tempers TrumpRx Expectations in 2026
CMS administrator Chris Klomp clarified TrumpRx targets the uninsured, not most Americans, countering President Trump's broader claims about the drug discount platform.
By Robert Kim
Creatinine vs Cystatin C GFR Accuracy in Moderate CKD
A BMJ cohort study finds combined creatinine and cystatin C equations outperform creatinine-alone GFR estimates in monitoring moderate chronic kidney disease.
Eli Lilly's Retatrutide Cuts Blood Sugar & Weight in Trial
Eli Lilly's triple-G drug retatrutide showed significant HbA1C and weight reductions in type 2 diabetes patients at 40 weeks in a 2026 late-stage trial.
How a Texas Couple Got Rich Off Out-of-Network Bills
Scott and Alla LaRoque built wealth through HaloMD, exploiting federal arbitration meant to protect patients from surprise medical bills.
By Sarah Tanaka
J&J's Icotyde: First Oral Psoriasis Pill FDA Approved 2026
The FDA approved icotrokinra (Icotyde) in March 2026, marking the first oral once-daily pill in its class for moderate to severe plaque psoriasis.
By James Liu
GOLDEN BRIDGE II Trial: CDSS Improves Stroke Outcomes
A cluster RCT of 21,603 stroke patients across 77 Chinese hospitals shows AI-powered clinical decision support significantly reduces vascular events.
By Priya Patel
ARPA-H Develops FDA-Authorized AI Agents for Clinical Use
ARPA-H is advancing FDA-authorized AI clinical tools in 2026, pairing federal research funding with mandatory clinical trial validation and deployment pathways.
By Robert Kim
FDA Approves High-Dose Wegovy 7.2mg for Obesity in 2026
The FDA approved high-dose semaglutide 7.2mg (Wegovy) for obesity, showing 18.7% mean weight loss in Phase 3 trials amid new Trump administration drug pricing agreements.
By Sarah Tanaka
Medicare Chief: TrumpRx Is Narrow in Scope, Not a Full Fix
Medicare chief Chris Klomp says TrumpRx is a limited cash-pay tool, not a sweeping drug pricing overhaul, tempering Trump's transformative claims.
Cancer Cells Surface Proteins: New Immunotherapy Targets 2026
UCSF researchers found oncogenic protein Src on cancer cell surfaces, potentially creating new immunotherapy targets for hard-to-treat solid tumors.
By Priya Patel
MedPAC 2026: $76B Medicare Advantage Overpayment Warning
MedPAC projects $76 billion in excess Medicare Advantage payments in 2026, urging Congress to reform spending as industry pressure mounts.
By Sarah Tanaka
Trump Drug Pricing & GSK Asthma Inhaler Controversy 2026
The White House pushes most-favored-nation drug pricing legislation while a Senate report scrutinizes GSK's asthma inhaler discontinuation strategy.
Aldeyra Therapeutics FDA Review: Red Flags & Short Sellers
Aldeyra Therapeutics faces FDA scrutiny amid short-seller pressure as its regulatory decision window approaches. What clinicians need to know in 2026.
By James Liu
PHILA Trial: Pyrotinib Survival Results in HER2+ Breast Cancer
Long-term PHILA trial data show pyrotinib plus trastuzumab and docetaxel delivers significant survival benefit in HER2-positive metastatic breast cancer.
Oral Obesity Pill Phase 2 Results & Cholesterol Guidelines 2026
Structure Therapeutics reports 16% weight loss in Phase 2 oral GLP-1 trial, plus GSK's Arexvy expansion and new cholesterol guideline updates.
Tourette Syndrome: Why Media Distortion Harms Clinical Care
When media reduces Tourette syndrome to debates about offense, patients face real clinical consequences. Here's what the coverage gets wrong.
By Robert Kim
UK Government Plans Space-Based Pharmaceutical Manufacturing
The UK government is collaborating with four regulatory bodies to establish a framework for manufacturing complex biologics in orbit using microgravity.
By Priya Patel
Regulating Invasive Cosmetic Procedures to Reduce Harm
Adverse events and regulatory gaps in cosmetic procedures prompt calls for structural reform, following high-profile cases like the 2024 death of Alice Webb after a BBL.
By Sarah Tanaka
Radial: $3.5B Nonprofit Reshaping Science for AI Era
Seemay Chou launches Radial, a $3.5B nonprofit funding bold, high-risk science projects and building AI-ready data infrastructure like the Diffuse database.
By Sarah Tanaka
Updated NICE Guidance: Chronic Heart Failure in Adults
NICE updates chronic heart failure guidance, covering pharmacological optimisation across ejection fraction subtypes and IV iron supplementation recommendations.
NHS Advice & Guidance Referral Rules Put Patients at Risk
GP leaders warn that NHS England's expanded advice and guidance referral system risks harmful delays and undermines clinical autonomy for family physicians.
Doctors Need Humility to Combat Health Misinformation
Experts at the Nuffield Trust Summit say clinicians must respond to patient-sourced misinformation with professional humility, not dismissal.
By Robert Kim
Best Drugs to Prevent Postoperative Delirium in Older Adults
A 2026 BMJ network meta-analysis evaluates pharmacological interventions to prevent postoperative delirium in older surgical patients across randomized trials.
By Priya Patel
Trump Drug Prices: Public Opinion vs. Biotech Pushback
A KFF poll reveals partisan divides on Trump drug pricing confidence, while biotech firms publicly challenge the most-favored nation pricing proposal.
By James Liu
Lancet Correction: Prostate Cancer Radiotherapy Meta-Analysis
The Lancet issued a correction for figure-labeling errors in a 2026 meta-analysis on hormone therapy and radiotherapy for recurrent prostate cancer.
By Sarah Tanaka
FDA Targets Telehealth GLP-1 Compounders in 2026 Crackdown
FDA has warned 70+ telehealth companies over compounded GLP-1 drugs, with scrutiny now extending to affiliated medical groups and prescribing networks.
By Robert Kim
Camrelizumab Plus CAPOX Improves Survival in Gastric Cancer
Phase 3 trial shows camrelizumab plus CAPOX with maintenance therapy significantly improves overall survival vs CAPOX alone in HER2-negative gastric cancer.
Prenatal Antiseizure Drugs & Neurodevelopmental Risk in Kids
A large US cohort study finds valproate and zonisamide carry the highest neurodevelopmental risks in children exposed prenatally to antiseizure medications.
Radial Launches with $500M to Modernize Science for AI Era
Scientist Seemay Chou launches Radial with $500M to reform scientific data infrastructure and systems underlying AI-driven life sciences research.
By Priya Patel
Wegovy Linked to Higher Ischemic Optic Neuropathy Risk
New FAERS analysis finds Wegovy carries nearly fivefold higher ischemic optic neuropathy risk vs. Ozempic, raising ocular safety concerns for GLP-1 drugs.
By Sarah Tanaka
Big Pharma Antibiotic Pipelines Shrink 35% in Five Years
Major drugmakers reduced antimicrobial development programs from 92 to 60 over five years, raising alarm over the global response to antibiotic resistance.
By Robert Kim
AMI's $1B Funding Round: Impact on Health AI Startup Nabla
Yann LeCun's AMI raises $1 billion in early 2026, sparking health tech interest due to its leadership ties with clinical AI firm Nabla.
By Priya Patel
NHS Halts Cross-Sex Hormones for Under 18s in England
NHS England suspends gender-affirming cross-sex hormone prescriptions for under-18s, launching a 90-day consultation on permanently removing the treatment.
By James Liu
BioNTech Founders Depart, Senator Probes FDA Rare Disease
BioNTech co-founders plan to leave by 2026 to launch a new mRNA venture, while a U.S. senator investigates FDA's rare disease drug approval denials.
By James Liu
Rising Autism & ADHD Diagnoses: Awareness or True Increase?
Global ASD and ADHD diagnoses have surged over two decades. Evidence suggests this reflects correcting historic underdiagnosis, not a true prevalence increase.
By James Liu
Jewish Doctor Suspended for Islamophobic Comments in UK
A UK tribunal suspended GP Cinderella Nonoo-Cohen for four months after she made Islamophobic remarks toward a Muslim colleague on a WhatsApp forum.
Martha's Rule: 446 Lifesaving NHS Interventions in 16 Months
NHS England reports 446 potentially lifesaving interventions in 16 months under Martha's Rule, the patient-initiated clinical escalation pathway launched in 2024.
FDA Reduces Advisory Meetings Amid Controversial Decisions
The FDA is cutting back on public advisory committee meetings as contested drug approval decisions mount, raising transparency concerns for patients nationwide.
By Priya Patel
FDA Advisory Committees Decline & Biosimilar Rule Changes
FDA faces scrutiny over a 63% drop in advisory committee meetings in 2025 and new moves to ease biosimilar development requirements in 2026.